NASDAQ:TWST - Twist Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.41 +0.13 (+0.56 %)
(As of 03/22/2019 02:29 AM ET)
Previous Close$23.28
Today's Range$21.86 - $24.14
52-Week Range$12.38 - $34.46
Volume59,102 shs
Average Volume49,110 shs
Market Capitalization$655.95 million
P/E Ratio-0.92
Dividend YieldN/A
BetaN/A
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.43 million

Profitability

Miscellaneous

Employees289
Market Cap$655.95 million
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corp (NASDAQ:TWST) posted its earnings results on Thursday, February, 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.33. The business had revenue of $11.49 million for the quarter, compared to analysts' expectations of $9.70 million. View Twist Bioscience's Earnings History.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Twist Bioscience.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience updated its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47-49 million, compared to the consensus revenue estimate of $47.37 million.

What price target have analysts set for TWST?

3 Wall Street analysts have issued 1 year price objectives for Twist Bioscience's stock. Their forecasts range from $25.99 to $25.99. On average, they expect Twist Bioscience's stock price to reach $25.99 in the next year. This suggests a possible upside of 11.0% from the stock's current price. View Analyst Price Targets for Twist Bioscience.

What is the consensus analysts' recommendation for Twist Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Twist Bioscience.

Has Twist Bioscience been receiving favorable news coverage?

Press coverage about TWST stock has trended somewhat negative on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Twist Bioscience earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include New Age Beverages (NBEV), Micron Technology (MU), Balchem (BCPC), Constellation Brands (STZ), Mid-America Apartment Communities (MAA), Alibaba Group (BABA), AAR (AIR), Amarin (AMRN), Lendlease Group (LLC) and United States Brent Oil Fund (BNO).

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the folowing people:
  • Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. (Age 57)
  • Mr. William Charles Banyai, COO & Director (Age 64)
  • Mr. Bill Peck, Chief Technology Officer (Age 59)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

When does the company's lock-up period expire?

Twist Bioscience's lock-up period expires on Monday, April 29th. Twist Bioscience had issued 5,000,000 shares in its initial public offering on October 31st. The total size of the offering was $70,000,000 based on an initial share price of $14.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (4.48%), Apoletto Ltd (1.63%), BlackRock Inc. (1.21%), Intellectus Partners LLC (1.04%), Massachusetts Financial Services Co. MA (0.79%) and Emerald Advisers LLC (0.59%). View Institutional Ownership Trends for Twist Bioscience.

Which major investors are buying Twist Bioscience stock?

TWST stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Apoletto Ltd, BlackRock Inc., Intellectus Partners LLC, Massachusetts Financial Services Co. MA, Emerald Advisers LLC, Artal Group S.A. and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for Twist Bioscience.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $23.41.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $655.95 million and generates $25.43 million in revenue each year. The company earns $-71,230,000.00 in net income (profit) each year or ($25.51) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is http://www.twistbioscience.com.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 455 MISSION BAY BOULEVARD SOUTH SUITE 545, SAN FRANCISCO CA, 94158. The company can be reached via phone at 800-719-0671 or via email at [email protected]


MarketBeat Community Rating for Twist Bioscience (NASDAQ TWST)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote "Outperform" if you believe TWST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: Why do corrections happen?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel